Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | AGL | P35573 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6861278 | 1.00 | CHRM2 (0.35) | CHRM2CHRM1CHRM3SLC1A2SPHK1 | |
| SCHEMBL2677786 | 1.00 | CHRM2 (0.35) | CHRM2CHRM1CHRM3SLC1A2SPHK1 | |
| SCHEMBL24039255 | 0.83 | MAPK1 (0.37) | CHRM2CHRM1CHRM3SLC1A2HRH3 | |
| SCHEMBL5728913 | 0.82 | MAPK1 (0.37) | CHRM2CHRM1CHRM3SLC1A2HRH3 | |
| SCHEMBL6861146 | 0.79 | CHRM2 (0.33) | CHRM2CHRM1CHRM3SLC1A2HRH3 | |
| SCHEMBL18421811 | 0.79 | SLC1A2 (0.32) | CHRM2CHRM1CHRM3SLC1A2HRH3 | |
| SCHEMBL15955579 | 0.79 | SLC1A2 (0.32) | SLC1A2 | |
| SCHEMBL201157 | 0.79 | SPHK1 (0.38) | CHRM2CHRM3SLC1A2SPHK1AGL | |
| SCHEMBL201158 | 0.79 | SPHK1 (0.38) | CHRM2CHRM3SLC1A2SPHK1AGL | |
| SCHEMBL178593 | 0.79 | SPHK1 (0.38) | CHRM2CHRM3SLC1A2SPHK1AGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615568-B2 | 3-[2-(cis-4-aminocyclohexyloxy)-4-methylsulfonylbenzoyl-amino]-N-(5-chloropyridin-2-yl)pyridine-2-carboxamide,; anticoagulant; platelet glycoprotein receptor antagonist; thrombosis; orally; acylation of amino-pyridine by (methylthio)benzoic acid followed by oxidation, alkylation, carbonylation | ELI LILLY AND COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080108594-A1 | Antithrombotic Ethers | ELI LILLY AND COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| EP-1237862-A1 | SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | Versicor, Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001044179-A1 | NOVEL SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | VERSICOR, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108594-A1 | Antithrombotic Ethers | F11, SERPINC1, F2 | CHRM2 4670/4885CHRM1 3800/4885CHRM3 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.